Combination of HDAC inhibitor with IL-2 promising

Efficacious proteasome/HDAC inhibitor combination therapy for primary effusion lymphoma.

Primary effusion lymphoma (PEL) is a rare form of aggressive B cell lymphoma caused by Kaposi's sarcoma-associated herpesvirus (KSHV). Current chemotherapy approaches result in dismal outcomes, and there is an urgent need for new PEL therapies. Previously, we established, in a direct xenograft model of PEL-bearing immune-compromised mice, that treatment with the proteasome inhibitor, bortezomib...

Improving Insulin Sensitivity With HDAC Inhibitor

Histone deacetylase (HDAC) has emerged as a new molecular target in the control of obesity and type 2 diabetes. HDAC is an enzyme with well-known functions in the regulation of chromatin structure and gene transcription in the nucleus, where HDAC interacts with corepressor proteins such as NcoR and SMRT to form active corepressor complexes. In the corepressor complex, HDAC catalyzes removal of ...

HDAC and HDAC Inhibitor: From Cancer to Cardiovascular Diseases

Histone deacetylases (HDACs) are epigenetic regulators that regulate the histone tail, chromatin conformation, protein-DNA interaction, and even transcription. HDACs are also post-transcriptional modifiers that regulate the protein acetylation implicated in several pathophysiologic states. HDAC inhibitors have been highlighted as a novel category of anti-cancer drugs. To date, four HDAC inhibit...

Regulation of HDAC Inhibitor-Triggered Autophagy

Autophagy is an essential process of the eukaryotic cell allowing degradation and recycling of dysfunctional or non-functional cellular components either in response to physiological or pathological changes [1]. Beside proteasomemediated degradation, baseline autophagy serves as a major cellular pathway for long-lived protein and organelle turnover maintaining a well-balanced equilibrium betwee...

HDAC ) inhibitor , and prediction of human pharmacokinetics